A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 70
Updated:6/29/2018
Start Date:January 2013
End Date:December 2019
Contact:Allen Lee, MD
Phone:(734) 936-9454

Use our guide to learn which trials are right for you!

A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis

Gastroparesis is a disorder characterized by impaired gastric emptying in the absence of
obstruction in the proximal GI tract. It is a common condition affecting up to 5 million
persons in the United States alone. Despite this, metoclopramide is currently the only FDA
approved medication for the treatment of gastroparesis. However, the evidence supporting
metoclopramide in gastroparesis is fairly weak and was recently issued a black box warning
because of potential irreversible side effects. There is clearly an urgent need for newer
therapeutic options with better efficacy and tolerability. Olanzapine is a second generation
anti-psychotic that is currently FDA approved for the treatment of schizophrenia and bipolar
disorder. Because of actions at several receptors throughout the body, including dopamine and
serotonin receptors, Olanzapine may provide anti-nausea and pro-motility effects in the
stomach. Long-term use of olanzapine may also increase plasma levels of ghrelin. Ghrelin is a
hormone produced by the gut that stimulates appetite and has also been shown to have
beneficial effects on gastroparesis. The investigators hypothesize that olanzapine will be
effective and safe in controlling symptoms as well as stimulate appetite and weight gain in
gastroparesis. The investigators also hypothesize that olanzapine will stimulate gastric
motility. Finally, the investigators hypothesize that olanzapine will modulate the secretion
of ghrelin in gastroparesis. This pilot study may provide further information on the efficacy
and safety of olanzapine in gastroparesis which could be utilized in a larger randomized,
prospective study in the future.


Inclusion Criteria:

- Male or female between 18 and 70 years of age

- Must have a > or = 6 month history of relevant symptoms of gastroparesis, (e.g.,
chronic post-prandial fullness, early satiety, postprandial nausea), patients will
have a mean of the daily scores over a minimum of 7 days indicating > or = mild (2)
and < or = severe (4) post-prandial fullness assessed using the GCSI-DD during the
screening period prior to randomization

- Documented abnormal gastric emptying within the past 2 years

- Has gastroparesis at screening (gastric half-time of emptying > upper limit of normal
as determined by wireless motility capsule)

- BMI between 18 - 30 kg/m2

- A female subject is eligible to participate if she is of non-childbearing potential or
child-bearing potential and agrees to use one of the approved contraception methods.
Female patients must agree to use contraception for at least 5 days following the last
dose of study medication

- Subject has never had a gastrectomy, nor major gastric surgical procedure or any
evidence of bowel obstruction or strictures within the previous 12 months

- Dosage of any concomitant medications has been stable for at least 3 weeks.

- Estimated (or measured) glomerular filtration rate ≥ 30 mL/min

- QTcB or QTcF < 450 msec or QTc < 480 msec in patients with Bundle Branch. Block based
on single or average QTc value of triplicate values obtained over a brief recording
period

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form

- AST and ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN; normal CBC, TSH,
and prolactin levels

Exclusion Criteria:

- History of diabetes mellitus or hyperglycemia

- History of cardiovascular or cerebrovascular disease

- History of hyperlipidemia

- History of cardiac arrhythmia or long QT syndrome

- History of seizure disorder

- History of hyperprolactinemia

- History of renal dysfunction

- History of hepatic impairment

- History of schizophrenia, bipolar disorder, or previous use of olanzapine

- History of Parkinson's disease, dementia or severe cognitive impairment

- History of GI surgery or placement of gastric pacemaker

- History of cardiac pacemaker or implantable cardiac defibrillator

- History of eating disorder

- History of intrapyloric botulinum toxin injections

- Subject is on chronic enteral or parenteral feeding

- Subject has pronounced dehydration

- Subject has evidence of severe cardiovascular autonomic neuropathy (e.g. history of
recurrent syncope in the last 6 months)

- Use of medications potentially influencing upper gastrointestinal motility or appetite
within one week of the study (e.g., prokinetic drugs, macrolide antibiotics
(erythromycin), GLP-1 mimetics)

- Regular opiate use

- Subjects who are taking drugs that potentially interact with olanzapine including
diazepam, lorazepam, alcohol, carbamazepine, fluvoxamine, olanzapine and fluoxetine in
combination, CNS acting drugs, levodopa and dopamine agonist, and olanzapine when used
in combination with lithium or valproate

- History or presence of clinically significant gastro-intestinal, hepatic or renal
disease or other condition that would in the opinion of the investigator or medical
monitor make the subject unsuitable for inclusion in this clinical study

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer)

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator would make
the subject unsuitable for inclusion in this clinical study

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day time-period

- Pregnant females as determined by positive serum or urine hCG test (from the first
urine of the day) at screening or prior to dosing

- Lactating females

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome or asymptomatic gallstones)

- Subject is unable to swallow pills
We found this trial at
2
sites
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Allen Lee, MD
Phone: 734-936-9454
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Braden Kuo, MD
Phone: 617-726-0196
?
mi
from
Boston, MA
Click here to add this to my saved trials